ClinicalTrials.gg
CompletedNCT00980876Updated Apr 17, 2015

A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension

A Phase 3 interventional study of Cipro HC and Ciprofloxacin HCl and Hydrocortisone in Otitis Externa, sponsored by Farmoquimica S.A.. Completed at 1 site in Brazil. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2015-04-17.

Sponsored by Farmoquimica S.A. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
1 Year to 70 Years
Sex
All
01

Study summary

The objective of this study is to compare the efficacy and safety profiles of the test product containing 2 mg/mL ciprofloxacin hydrochloride associated with 10 mg/mL of hydrocortisone with the reference product Cipro HC®, in patients with acute otitis externa.

Read the detailed description

Phase III, non inferiority, multicentric, controlled, single blind, parallel-group, randomized study.

Population: 224 patients with external otitis , men and women aged between 1 - 70 years.

Primary endpoint: The primary endpoint of this study is the elimination of pain, swelling and otorrhea (cure).

Secondary endpoint: The endpoint will be the identification of the side effects of medication use.

02

Conditions studied

  • Otitis Externa

Browse trials for

03

In context

Otitis Externa

22 studies on the registry are indexed under Otitis Externa; 1 is open to participants now.

This study's enrollment of 224 is above the median of 100 across 20 interventional studies indexed under Otitis Externa.

Browse Otitis Externa studies →

Lead sponsor

Farmoquimica S.A. is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Informed of the nature of the study and given written ;
  • Patients with acute otitis externa;
  • Intact tympanic membrane.

Exclusion criteria

Exclusion Criteria:

  • Known allergy or sensitivity to Ciprofloxacin Hydrochloride and Hydrocortisone;
  • Patient has the tympanic membrane not intact;
  • Diabetes
  • Bilateral Acute Otitis Externa;
  • Pregnant or lactating patients;
  • Overt fungal Acute Otitis Externa;
  • Other diseases of the ear
  • Current Infection requiring systemic antimicrobial therapy.
  • Current enrollment in an drug or device study or participation in such a study within 30 days of entry into this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
224 participants (actual)

Study arms

  • Active comparator
    Cipro HC

    Reference product

    Drug: Cipro HC

  • Experimental
    Ciprofloxacin HCl and Hydrocortisone

    Test product

    Drug: Ciprofloxacin HCl and Hydrocortisone

Interventions

  • DrugCipro HC

    Cipro HC (Ciprofloxacin HCl and Hydrocortisone)

  • DrugCiprofloxacin HCl and Hydrocortisone

    Drug pages: Ciprofloxacin · Hydrocortisone

    Ciprofloxacin Hydrochloride and Hydrocortisone

    Also known as: Otociriax

06

What researchers measure

Primary outcomes

  1. Cure (reduced pain, swelling and otorrhea)

    Time frame: 7 days

Secondary outcomes

  1. Identification of possible side effects

    Time frame: 7 days

07

Study locations

1 site
  • Clínica Quiron
    Campinas, São Paulo 13087-000, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2009
First posted
Sep 21, 2009
Start
Apr 2012
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Last update
Apr 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00980876
Lead sponsor
Farmoquimica S.A.
Collaborators
Pharmagenix Projetos em Medicina Farmacêutica Ltda.
Responsible party
Sponsor
First posted
Sep 21, 2009
Start date
Apr 2012
Primary completion
Jan 2015
Completion
Jan 2015
Last update
Apr 17, 2015

Study contacts

Agricio N. Crespo, Phd
principal investigator · Clínica Quiron

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ciprofloxacin · Hydrocortisone

Start the discussion